Targeting PI3K in cancer: mechanisms and advances in clinical trials
TLDR
A critical review is performed to summarize the role of the PI3K pathway in tumor development, recentPI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3k inhibition.Abstract:
Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer. Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression. PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors. In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.read more
Citations
More filters
Journal ArticleDOI
Therapeutic Targeting of the Tumor Microenvironment
TL;DR: A comprehensive analysis of the current therapies targeting the tumor microenvironment (TME) is provided in this paper, combining a discussion of the underlying basic biology with clinical evaluation of different therapeutic approaches, and highlighting the challenges and future perspectives.
Journal ArticleDOI
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
TL;DR: This review outlines the emerging diversity of the genetic alterations that lead to activated PI3K-AKT-mTOR signaling in prostate cancer, and discusses new mechanistic insights into the interplay between the PI3k-AKt- mTOR pathway and several key interacting oncogenic signaling cascades that can cooperate to facilitate prostate cancer growth and drug-resistance.
Journal ArticleDOI
Trends in kinase drug discovery: targets, indications and inhibitor design.
Misty M. Attwood,Doriano Fabbro,Aleksandr V. Sokolov,Stefan Knapp,Stefan Knapp,Helgi B. Schiöth,Helgi B. Schiöth +6 more
TL;DR: In this paper, the authors analyzed the landscape of approved and investigational therapies that target kinases and trends within it, including the most popular targets of kinase inhibitors and their expanding range of indications.
Journal ArticleDOI
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.
TL;DR: This Review summarizes common genomic and chromosomal copy number abnormalities in ccRCC, providing a mechanistic framework with which to organize these features into initiating events, drivers of progression and factors that confer lethality.
Journal ArticleDOI
Sex differences in cancer mechanisms.
Joshua B. Rubin,Joseph Lagas,Lauren Broestl,Jasmin Sponagel,Nathan Rockwell,Gina Rhee,Sarah F. Rosen,Si Chen,Robyn S. Klein,P. I. Imoukhuede,Jingqin Luo +10 more
TL;DR: The goal in this review is to cover some of the robust sex differences that exist in core cancer pathways and to make the case for inclusion of sex as a biological variable in all laboratory and clinical cancer research.
References
More filters
Journal ArticleDOI
AKT/PKB signaling: navigating downstream.
TL;DR: Those Akt substrates that are most likely to contribute to the diverse cellular roles of Akt, which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration are discussed.
Journal ArticleDOI
PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Jing Li,Clifford Yen,Danny Liaw,Katrina Podsypanina,Shikha Bose,Steven I. Wang,Janusz Puc,Christa Miliaresis,Linda Rodgers,Richard W. McCombie,Sandra H. Bigner,Beppino C. Giovanella,Michael Ittmann,B. Tycko,Hanina Hibshoosh,Michael Wigler,Ramon Parsons +16 more
TL;DR: The PTEN product has a protein tyrosine phosphatase domain and extensive homology to tensin, a protein that interacts with actin filaments at focal adhesions as discussed by the authors.
Journal ArticleDOI
High frequency of mutations of the PIK3CA gene in human cancers
Yardena Samuels,Zhenghe Wang,Alberto Bardelli,Natalie Silliman,Janine Ptak,Steve Szabo,Hai Yan,Adi F. Gazdar,Steven M. Powell,Gregory J. Riggins,James K V Willson,Sanford D. Markowitz,Kenneth W. Kinzler,Bert Vogelstein,Victor E. Velculescu +14 more
TL;DR: To determine if PI3Ks are genetically altered in tumorigenesis, they were sequenced in human for the first time and the results allowed us to assess the importance of phosphatidylinositol 3-kinases in neoplasia.
Journal ArticleDOI
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
TL;DR: In light of the recent advances in understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, the exciting therapeutic opportunities for targeting this pathway to treat these diseases are discussed.
Journal ArticleDOI
Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN
Vuk Stambolic,Vuk Stambolic,Akira Suzuki,Akira Suzuki,José Luis de la Pompa,José Luis de la Pompa,Christine Mirtsos,Christine Mirtsos,Takehiko Sasaki,Takehiko Sasaki,Jürgen Ruland,Jürgen Ruland,Josef M. Penninger,Josef M. Penninger,David P. Siderovski,David P. Siderovski,Tak W. Mak,Tak W. Mak +17 more
TL;DR: The results show that PTEN may exert its role as a tumor suppressor by negatively regulating the PI3'K/PKB/Akt signaling pathway.